Document is current
Any future updates will be listed below
-
Authors
Zhang, Yue
Martinez, Jonathan
Tercan, Bahar
Kuusanmäki, Heikki
Emmert-Streib, Frank
Chandraseelan, Jerome G.
Farea, Amer
Yli-Harja, Olli
Heckman, Caroline A.
Gibbs, David L.
Thorsson, Vesteinn
Shmulevich, Ilya
Kontro, Mika
Qin, Guangrong
Aguilar, Boris
-
Funding
Funding for this research was provided by:
National Institutes of Health (R01CA270210, R01CA270210, R01CA270210, R01CA270210, R01CA270210, R01CA270210, R01CA270210, R01CA270210, R01CA270210, R01CA270210, R01CA270210, R01CA270210, R01CA270210, R01CA270210, R01CA270210)
Research Council of Finland (352265, 352265, 352265, 352265, 352265, 352265, 352265)
Sigrid Juselius Foundation
- License Information
-
More Information
Article History
Received: 31 August 2024
Accepted: 26 August 2025
First Online: 6 October 2025
Competing interests
: M.K. reports personal fees (Astellas Pharma, AbbVie, Bristol-Myers Squibb, Faron Pharmaceuticals, Novartis and Pfizer) and research funding (AbbVie, outside the submitted work). C.A.H. has received personal fees from Amgen and research funding from Kronos Bio, Novartis, Oncopeptides, WNTResearch, and Zentalis Pharmaceuticals for work outside of the submitted work. Y.Z., J.M., B.T., H.K., F.E.S., J.C., A.F., O.Y.H., D.G., V.T., I.S., G.Q., B.A. report no competing interests.
